WHC is still in active development. Read this to understand our approach.
depiction of HQVHOQAKMCMIIM-UHFFFAOYSA-N.svg
isomerdesign

WIN 55,212-2

Verificar en isomerdesign

isomerdesign

LSM-15495

Verificar en isomerdesign

drugmap

WIN-55212-2

Verificar en drugmap

drugmap

WIN-55212-2

Verificar en drugmap

wiki

WIN 55,212-2

Verificar en wiki

Data

InChI: InChI=1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3

Sinónimos: WIN55212-2,WIN 55,212-2, 134959-51-6, UNII-5H31GI9502, [5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone, CHEBI:73295, (r)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone, (5-Methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino-[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone,(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3.de)-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone], 131543-22-1,LSM-15495, CTK4B9570, (2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate, (5-methyl-3-(morpholinomethyl)-2,3-dihydro-[1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1-yl)methanone, CHEMBL283206, 5H31GI9502,131513-18-3, SCHEMBL3680086, WIN 55212-2, HQVHOQAKMCMIIM-UHFFFAOYSA-N, AC1Q5GBM,WIN 55,212-3, WIN 55,212-2,WIN-55,212-2, AC1L1KWZ,[3H]WIN55212-2,Win-55212-2, [(3R)-5-methyl-3-(morpholin-4-ylmethyl)-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl](1-naphthyl)methanone, CHEMBL188, GTPL736

Estimated data

Solubilidad: -4.965 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 61.6% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.